Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Belite Bio Inc ADR (BLTE)

Belite Bio Inc ADR (BLTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,962,841
  • Shares Outstanding, K 30,612
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,630 K
  • EBIT $ -36 M
  • EBITDA $ -35 M
  • 60-Month Beta -1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.31
  • Low Estimate -0.36
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -36.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.00 +6.87%
on 12/16/24
82.89 -22.64%
on 11/21/24
-18.41 (-22.31%)
since 11/20/24
3-Month
43.70 +46.73%
on 09/26/24
86.53 -25.90%
on 11/14/24
+15.68 (+32.37%)
since 09/20/24
52-Week
31.00 +106.81%
on 04/17/24
86.53 -25.90%
on 11/14/24
+19.62 (+44.09%)
since 12/20/23

Most Recent Stories

More News
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

BLTE : 64.12 (+1.07%)
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

BLTE : 64.12 (+1.07%)
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

BLTE : 64.12 (+1.07%)
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

BLTE : 64.12 (+1.07%)
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

BLTE : 64.12 (+1.07%)
Why Shares of Belite Bio Soared This Week

The clinical-stage biotech company bounced back from a 52-week low late last week.

AMD : 119.21 (+0.28%)
BLTE : 64.12 (+1.07%)
Why Shares of Belite Bio Are Slumping Wednesday

The biopharmaceutical company announced a stock sale that's not great news to current investors.

AMD : 119.21 (+0.28%)
BLTE : 64.12 (+1.07%)
3 Breakout Growth Stocks to Buy for the Long Haul

These three have had big-time share gains backed up by breakthrough science.

BLTE : 64.12 (+1.07%)
TMDX : 61.70 (+1.93%)
RYTM : 56.12 (+1.15%)
2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023

Find out how these stock rockets could continue their ascent.

BLTE : 64.12 (+1.07%)
TMDX : 61.70 (+1.93%)
3 Soaring Biotech Stocks That Could Climb Much Higher

These drugmakers have bucked the overall market's downward trend this year and expectations are still high.

BLTE : 64.12 (+1.07%)
CINC : 29.06 (-0.48%)
PLRX : 13.21 (-0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases....

See More

Key Turning Points

3rd Resistance Point 69.41
2nd Resistance Point 67.66
1st Resistance Point 65.89
Last Price 64.12
1st Support Level 62.36
2nd Support Level 60.61
3rd Support Level 58.84

See More

52-Week High 86.53
Fibonacci 61.8% 65.32
Last Price 64.12
Fibonacci 50% 58.77
Fibonacci 38.2% 52.22
52-Week Low 31.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar